HKT288 in Solid Tumors, Including Epithelial Ovarian Cancer and Renal Cell Carcinoma
Stopped early · Phase 1
Conditions studied: Epithelial Ovarian Cancer, Renal Cell Carcinoma
In brief
A first-in-human study using HKT288 in solid tumors, including epithelial ovarian cancer and renal cell carcinoma
Key facts
- Study ID
- NCT02947152
- Run by
- Novartis Pharmaceuticals
- People needed
- 9
- Starts
- 2016-12-01
- Expected to finish
- 2017-09-14
- Last updated by the study team
- 2020-12-08
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Novartis Investigative Site — Houston, Texas, United States
- Novartis Investigative Site — Melbourne, Victoria, Australia
- Novartis Investigative Site — Leuven, Belgium
- Novartis Investigative Site — Nagoya, Aichi-ken, Japan
- Novartis Investigative Site — Barcelona, Catalonia, Spain
- Novartis Investigative Site — Locarno, Switzerland
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.